Smallest TEE for children

Join the Campaign to Help

American Cancer Society Guidelines for the Early Detection of Cancer

American Cancer Society Guidelines for the Early Detection of Cancer

The American Cancer Society recommends these cancer screening guidelines for most adults. Screening tests are used to find cancer before a person has any symptoms.
Diet and Physical Activity: What’s the Cancer Connection?

Diet and Physical Activity: What’s the Cancer Connection?

How much do daily habits like diet and exercise affect your risk for cancer? Much more than you might think. Research has shown that poor diet and not being active are 2 key factors that can increase a person’s cancer risk. The good news is that you do something about this.

TREATMENT

Cancer treatment is improving, saving lives and extending survival for many people. Depending on various factors, treatment options may include surgery, radiation, immunotherapy, chemotherapy, hormone therapy, or targeted, local therapy, among others. These treatments might be used alone or in combination. Clinical trials evaluate the benefits of new therapies and broaden the options available to patients.

This section includes treatment trends for cancer sites for which there are available data trends and definitive treatment guidelines based on rigorous evidence of benefit to patients, including bladder, breast, colorectal, kidney, lung, ovarian, and prostate cancers.
Know about your health

You’re smart. You’re responsible. You’re highly motivated to keep your family healthy – and having adequate health insurance coverage is part of that. But learning what you need to know about insurance in order to make good decisions can be overwhelming. That’s where we can help.

Philips announces world's smallest multiplane transesophageal transducer Important advance in care for pediatric cardiac patients Andover, Mass., USA – Royal Philips Electronics (NYSE: PHG, AEX: PHI) today

introduced its microTEE, the world’s smallest transesophageal echocardiography (TEE) transducer for cardiac imaging of neonatal patients. As part of the latest Vision release for the Philips iE33 intelligent echocardiography system, the microTEE transducer provides paediatric cardiologists with a diagnostic tool for imaging the hearts of newborn patients. Philips microTEE will be showcased next week at the 20th annual American Society of Echocardiography (ASE) in Washington, D.C. and will be available for sale globally this summer. Due to the larger size of previously available paediatric TEE transducers, small babies have been impossible to image during critical cardiac catheterization or surgical procedures. As a result, high-risk procedures have been done routinely on these tiny patients without transesophageal echocardiography images available to the interventionalist or surgeon. "The microTEE probe is a major advance in our ability to provide intra-operative cardiac imaging in newborn babies and infants,” said Dr. Girish Shirali, M.D., director of paediatric echocardiography at Medical University of South Carolina (MUSC) Children’s Hospital. “We are delighted with the image quality, and the miniaturization of the probe has already proven invaluable to our paediatric interventionalists in high-risk cath lab procedures. Finally, our smallest and sickest patients can be imaged intra-operatively just like everyone else.” Building on Philips’ existing 2D technology, the microTEE transducer is roughly one-third the size of previous pediatric TEE transducers, allowing physicians to ‘turn on the lights’ for the first time for their tinier patients and providing the images they need during interventional procedures. Available globally in summer 2009, the new microTEE is also entering trials for adult patients requiring TEE imaging but who have difficulty tolerating standard TEE probes. “We developed the microTEE in order to help even the smallest patients,” said Anne LeGrand, senior vice president and general manager, ultrasound, for Philips Healthcare. “MicroTEE is the latest in a series of industry ‘firsts’ offered on our iE33 premium cardiovascular platform. We continue to invest heavily in the iE33 to provide innovative, validated solutions that fulfill physicians’ needs and provide enhanced patient care.”